Comparative study of modulatory effects of Semax and primary proline-containing peptides on hemostatic reactions.
Cherkasova. K A KA; Lyapina. L A LA; Ashmarin. I P IP
Key Findings
- Intranasal Semax and Pro‑Gly‑Pro increased anticoagulant and fibrinolytic activity in rat plasma.
- Both peptides lowered antiplasmin levels, which normally block clot breakdown.
- Semax and Pro‑Gly‑Pro reduced the weight of thrombi in an experimental clot model.
Practical Outcomes
- The data suggest Semax might influence clotting pathways, which could be of interest for cardiovascular health or anti‑thrombotic strategies. However, the study is limited to rats, uses a 5‑day dosing regimen, and does not address safety or dosing in humans, so it’s not ready for direct self‑experimentation. Biohackers should treat this as early, exploratory evidence rather than a protocol to adopt.
Summary
In a short‑term rat study, giving the peptide Semax (and related proline‑rich peptides) through the nose boosted the blood’s ability to prevent clots and to break them down, and it made experimentally formed clots smaller.
Abstract
Intranasal administration of Semax, peptide Pro-Gly-Pro, and a mixture of peptides Pro-Gly+Gly-Pro to rats for 5 days enhanced anticoagulant and fibrinolytic potential of the plasma (total fibrinolytic activity and plasmin and plasminogen activator activities) and decreased antiplasmin concentration. Semax and Pro-Gly-Pro decreased the weight of thrombi during experimental thrombosis.
Study Information
pubmed
2001
10.1023/a:1012503606536